Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JOHN RUBINO

Allopathic & Osteopathic Physicians Internal Medicine

NPI
1962543280
CMS profile
43312
Location
RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$543.04

31 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $543.04 31

By paying entity

PY2022 · entire year · sorted by reported total

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JOHN RUBINO

NPI 1962543280 · CMS profile ID 43312

Allopathic & Osteopathic Physicians / Internal Medicine

RALEIGH, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JOHN RUBINO, NPI 1962543280, CMS profile ID 43312. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JOHN RUBINO, NPI 1962543280, CMS profile ID 43312, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–31 of 31 matching records. This page contains 31 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1962543280?year=2022&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

31 matching records · $543.04 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 31 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–31 of 31.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Horizon Therapeutics plc $16.5212/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 937684455 CMS
Lilly USA, LLC $18.3611/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918098477 CMS
Teva Pharmaceuticals USA, Inc. $15.3510/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954621585 CMS
OptiNose US, Inc. $23.3910/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928119391 CMS
AstraZeneca Pharmaceuticals LP $19.4610/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915518235 CMS
Sunovion Pharmaceuticals Inc. $24.8610/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 920953597 CMS
Merck Sharp & Dohme LLC $13.0109/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944235687 CMS
PFIZER INC. $16.7709/07/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949311707 CMS
SANOFI-AVENTIS U.S. LLC $16.9908/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 938743617 CMS
ABBVIE INC. $24.3008/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891489539 CMS
Novo Nordisk Inc $16.6208/10/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898800579 CMS
Boehringer Ingelheim Pharmaceuticals, Inc. $18.4707/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 887400393 CMS
Novo Nordisk Inc $15.3007/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898898965 CMS
Amgen Inc. $12.9507/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940055465 CMS
GlaxoSmithKline, LLC. $22.1307/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944344485 CMS
Lilly USA, LLC $11.7906/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 918095145 CMS
ABBVIE INC. $13.4106/15/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891489537 CMS
Novartis Pharmaceuticals Corporation $12.8506/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894304157 CMS
Novo Nordisk Inc $24.1605/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898800585 CMS
Novartis Pharmaceuticals Corporation $16.9205/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 894304153 CMS
Merck Sharp & Dohme LLC $12.9305/04/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944152885 CMS
E.R. Squibb & Sons, L.L.C. $16.8004/20/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 932626673 CMS
Amgen Inc. $13.5204/06/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939809907 CMS
Novo Nordisk Inc $20.5703/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898622349 CMS
ABBVIE INC. $15.6103/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 891489535 CMS
Novo Nordisk Inc $16.0402/23/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898549937 CMS
PFIZER INC. $21.4202/16/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949093417 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.6702/09/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 955803619 CMS
AstraZeneca Pharmaceuticals LP $11.9401/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914982131 CMS
Teva Pharmaceuticals USA, Inc. $16.6201/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954621143 CMS
Novo Nordisk Inc $24.3101/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 898800593 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $1,823.22 39
PY2020 $410.97 28
PY2021 $698.79 47
PY2022 $543.04 31
PY2023 $6,389.49 35
PY2024 $1,915.52 44
PY2025 $1,251.65 30

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $2,783,192.12 359
PY2024 Recipient $66,231.01 15
PY2024 Principal investigator $2,510,578.54 317
PY2023 Recipient $6,417.61 4
PY2023 Principal investigator $2,159,960.11 267
PY2022 Principal investigator $2,441,546.83 286
PY2021 Principal investigator $1,166,336.49 169
PY2020 Principal investigator $1,326,147.90 192
PY2019 Principal investigator $636,986.48 193

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

359 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $600.00 12/31/2025 Non-covered Recipient Entity
PMG RESEARCH INC
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine with an Open-Label Extension No dispute reported 06/30/2026 1202532318
Principal investigator 1 GlaxoSmithKline, LLC. $500.00 12/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168244
Principal investigator 1 BioNTech SE $2,148.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021721
Principal investigator 1 Hoffmann-La Roche Limited $14,143.00 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569392
Principal investigator 1 ModernaTX, Inc. $51,816.50 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991894
Principal investigator 1 ModernaTX, Inc. $8,325.75 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991906
Principal investigator 1 ModernaTX, Inc. $832.02 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991938
Principal investigator 1 ModernaTX, Inc. $4,237.80 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991970
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,506.95 12/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184278890
Principal investigator 1 PFIZER INC. $702.00 12/15/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228806697
Principal investigator 1 PFIZER INC. $702.00 12/15/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED CLINICAL STUDY EVALUATING THE SAFETY TOLERABILITY IMMUNOGENICITY AND EFFICACY OF A VARIANTADAPTED BNT162B2 VACCINE IN HEALTHY PARTICIPANTS 50 THROUGH 64 YEARS OF AGE No dispute reported 06/30/2026 1228806781
Principal investigator 1 PFIZER INC. $13,500.00 12/12/2025 Non-covered Recipient Entity
Accellacare US Inc
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228806692
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274444
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $376.65 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274450
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,626.75 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274452
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,050.00 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274454
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,108.10 12/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184274783
Principal investigator 1 ABBVIE INC. $5,869.80 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202528064
Principal investigator 1 BioNTech SE $2,507.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021697
Principal investigator 1 GlaxoSmithKline, LLC. $1,806.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168239
Principal investigator 1 Hoffmann-La Roche Limited $61.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569334
Principal investigator 1 Hoffmann-La Roche Limited $500.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569446
Principal investigator 1 Hoffmann-La Roche Limited $9,186.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569494
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,601.15 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269175
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269263
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,072.25 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269373
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269381
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $216.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 12/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184269391
Principal investigator 1 ModernaTX, Inc. $16,581.28 11/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991884
Principal investigator 1 ModernaTX, Inc. $832.02 11/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991886
Principal investigator 1 ModernaTX, Inc. $9,888.20 11/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991960
Principal investigator 1 ModernaTX, Inc. $8,815.50 11/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252992002
Principal investigator 1 ABBVIE INC. $1,397.75 11/26/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202525548
Principal investigator 1 BioNTech SE $4,655.00 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,493.50 11/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184264469
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228808864
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228808870
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228808876
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228808958
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228808964
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228809191
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228809273
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228809278
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228809285
Principal investigator 1 PFIZER INC. $426.60 11/24/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228809341
Principal investigator 1 Hoffmann-La Roche Limited $32,407.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569126
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $7,225.47 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263537
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263571
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $153.90 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263573
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263575
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,708.15 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263577
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $684.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263579
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/20/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184263589
Principal investigator 1 Novartis Pharmaceuticals Corporation $13.74 11/15/2025 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308046
Principal investigator 1 BioNTech SE $12,251.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021717
Principal investigator 1 BioNTech SE $138.42 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022054
Principal investigator 1 Hoffmann-La Roche Limited $50,666.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211568990
Principal investigator 1 Hoffmann-La Roche Limited $724.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569134
Principal investigator 1 Hoffmann-La Roche Limited $203.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569168
Principal investigator 1 Hoffmann-La Roche Limited $105.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569207
Principal investigator 1 Hoffmann-La Roche Limited $4,965.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569285
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,246.75 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261261
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $392.04 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261275
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $19,602.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261277
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,132.00 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261279
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,623.75 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,172.25 11/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184261283
Principal investigator 1 PFIZER INC. $180.80 11/12/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228806786
Principal investigator 1 PFIZER INC. $265.20 11/12/2025 Non-covered Recipient Entity
Accellacare Raleigh
A PHASE 3 PLACEBOCONTROLLED DOUBLEBLINDED RANDOMIZED STUDY TO EVALUATE THE EFFICACY SAFETY AND TOLERABILITY OF A CLOSTRIDIOIDES DIFFICILE VACCINE IN ADULTS 65 YEARS OF AGE AND OLDER No dispute reported 06/30/2026 1228806791
Principal investigator 1 BioNTech SE $1,386.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021699
Principal investigator 1 BioNTech SE $5,211.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021701
Principal investigator 1 BioNTech SE $2,772.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021703
Principal investigator 1 BioNTech SE $9,330.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021705
Principal investigator 1 BioNTech SE $8,012.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021707
Principal investigator 1 BioNTech SE $17,114.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021709
Principal investigator 1 BioNTech SE $5,014.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021711
Principal investigator 1 BioNTech SE $2,704.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021713
Principal investigator 1 BioNTech SE $2,704.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021715
Principal investigator 1 BioNTech SE $183.58 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021725
Principal investigator 1 BioNTech SE $183.58 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021727
Principal investigator 1 BioNTech SE $300.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021733
Principal investigator 1 BioNTech SE $700.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021735
Principal investigator 1 BioNTech SE $192.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021737
Principal investigator 1 BioNTech SE $90.42 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021739
Principal investigator 1 BioNTech SE $300.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021743
Principal investigator 1 BioNTech SE $300.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021745
Principal investigator 1 BioNTech SE $300.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021747
Principal investigator 1 BioNTech SE $300.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021749
Principal investigator 1 BioNTech SE $176.73 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022025
Principal investigator 1 BioNTech SE $90.42 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022049
Principal investigator 1 BioNTech SE $542.84 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022063
Principal investigator 1 BioNTech SE $131.52 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022077
Principal investigator 1 H. Lundbeck A S $2,000.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776593
Principal investigator 1 H. Lundbeck A S $1,500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776606
Principal investigator 1 H. Lundbeck A S $350.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776718
Principal investigator 1 H. Lundbeck A S $750.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776756
Principal investigator 1 H. Lundbeck A S $1,300.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251776760
Principal investigator 1 Hoffmann-La Roche Limited $31,464.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Phase 2 study to evaluate RO7795081 on participants with obesity or overweight with one comorbidity No dispute reported 06/30/2026 1211569240
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,905.07 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257849
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,653.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257927
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,425.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257977
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,172.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184257999
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $392.04 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258021
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,623.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258043
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $22,734.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258047
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258213
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258215
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,402.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258307
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,175.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258309
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,473.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258311
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $684.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258313
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $196.02 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258315
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,392.48 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258317
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $321.30 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258349
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258359
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $972.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258361
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $513.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258363
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $963.90 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258365
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $399.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258383
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,077.30 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258385
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258387
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258425
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $513.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258453
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,474.90 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258455
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $165.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258457
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,125.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258459
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $897.48 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258557
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $14,175.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258559
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,922.02 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258561
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $855.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258563
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,473.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258565
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $648.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258605
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258607
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,214.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258609
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258611
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,821.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258693
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258695
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $805.95 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258697
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258699
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258711
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,849.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258723
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $114.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258725
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258727
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $537.30 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258729
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258763
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,600.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258787
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $495.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258819
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $47.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258821
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $924.75 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258831
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,119.50 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258833
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $171.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258835
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $324.00 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258837
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,792.07 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258905
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,532.84 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184258949
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $10,720.90 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259071
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,312.88 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259137
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $20,540.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184259185
Principal investigator 1 TOLMAR, INC. $3,179.25 11/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323304
Principal investigator 1 ABBVIE INC. $44.55 11/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202523355
Principal investigator 1 ABBVIE INC. $318.60 11/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202523369
Principal investigator 1 ABBVIE INC. $3,205.91 11/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202522287
Principal investigator 1 BioNTech SE $155.68 11/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022059
Principal investigator 1 GlaxoSmithKline, LLC. $223.00 11/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168226
Principal investigator 1 ModernaTX, Inc. $2,496.06 10/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991898
Principal investigator 1 ModernaTX, Inc. $5,297.25 10/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991948
Principal investigator 1 ModernaTX, Inc. $9,128.94 10/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991958
Principal investigator 1 Amgen Inc. $81,876.55 10/24/2025 Non-covered Recipient Entity
ACELLACARE US INC
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638823
Principal investigator 1 GlaxoSmithKline, LLC. $1,077.30 10/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168391
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $192,292.65 10/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184250581
Principal investigator 1 BioNTech SE $58.00 10/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021719
Principal investigator 1 ABBVIE INC. $17,926.31 10/09/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202516119
Principal investigator 1 BioNTech SE $70.99 10/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022045
Principal investigator 1 GlaxoSmithKline, LLC. $1,862.95 10/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168223
Principal investigator 1 ABBVIE INC. $815.40 09/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202512874
Principal investigator 1 ABBVIE INC. $89.10 09/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202512876
Principal investigator 1 ABBVIE INC. $500.00 09/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202512878
Principal investigator 1 ModernaTX, Inc. $832.02 09/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991914
Principal investigator 1 ModernaTX, Inc. $15,538.60 09/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991934
Principal investigator 1 ModernaTX, Inc. $4,339.88 09/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991972
Principal investigator 1 ModernaTX, Inc. $8,521.65 09/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991990
Principal investigator 1 GlaxoSmithKline, LLC. $196.00 09/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168235
Principal investigator 1 GlaxoSmithKline, LLC. $294.00 09/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165108
Principal investigator 1 ABBVIE INC. $4,145.85 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202509858
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,905.07 09/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184235213
Principal investigator 1 GlaxoSmithKline, LLC. $2,048.20 09/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165112
Principal investigator 1 ABBVIE INC. $500.00 08/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202506405
Principal investigator 1 ABBVIE INC. $579.15 08/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202506433
Principal investigator 1 ABBVIE INC. $764.10 08/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202506435
Principal investigator 1 ModernaTX, Inc. $14,104.61 08/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991888
Principal investigator 1 ModernaTX, Inc. $10,167.21 08/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991910
Principal investigator 1 ModernaTX, Inc. $4,237.80 08/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991986
Principal investigator 1 H. Lundbeck A S $350.00 08/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251773792
Principal investigator 1 H. Lundbeck A S $350.00 08/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251773287
Principal investigator 1 ABBVIE INC. $8,074.35 08/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202503097
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 08/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168215
Principal investigator 1 GlaxoSmithKline, LLC. $4,986.30 08/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168219
Principal investigator 1 ABBVIE INC. $44.55 07/31/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202500558
Principal investigator 1 ModernaTX, Inc. $638.40 07/31/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991988
Principal investigator 1 ABBVIE INC. $1,031.40 07/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202500428
Principal investigator 1 ABBVIE INC. $601.34 07/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202500438
Principal investigator 1 ModernaTX, Inc. $2,118.90 07/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991896
Principal investigator 1 ModernaTX, Inc. $15,189.58 07/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991946
Principal investigator 1 ModernaTX, Inc. $2,389.98 07/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991964
Principal investigator 1 GlaxoSmithKline, LLC. $853.10 07/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192168230
Principal investigator 1 ABBVIE INC. $753.35 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497760
Principal investigator 1 ABBVIE INC. $500.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497762
Principal investigator 1 ABBVIE INC. $311.85 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497764
Principal investigator 1 ABBVIE INC. $106.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202497778
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214456
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 07/10/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184214466
Principal investigator 1 ABBVIE INC. $5,952.15 07/02/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202493993
Principal investigator 1 ModernaTX, Inc. $21,699.40 06/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991950
Principal investigator 1 ModernaTX, Inc. $8,475.60 06/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991954
Principal investigator 1 ModernaTX, Inc. $7,130.76 06/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252992006
Principal investigator 1 BioNTech SE $7,319.00 06/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022090
Principal investigator 1 BioNTech SE $300.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021877
Principal investigator 1 BioNTech SE $1,500.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021881
Principal investigator 1 BioNTech SE $97.27 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021960
Principal investigator 1 BioNTech SE $205.50 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021964
Principal investigator 1 BioNTech SE $192.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021968
Principal investigator 1 BioNTech SE $600.00 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021973
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,525.20 06/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184209382
Principal investigator 1 ModernaTX, Inc. $18,716.95 06/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991966
Principal investigator 1 ModernaTX, Inc. $8,933.04 06/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991968
Principal investigator 1 ModernaTX, Inc. $66,183.17 06/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991974
Principal investigator 1 BioNTech SE $93.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021832
Principal investigator 1 BioNTech SE $144.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022012
Principal investigator 1 BioNTech SE $264.00 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022015
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,067.39 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184206511
Principal investigator 1 TOLMAR, INC. $2,188.35 06/12/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323238
Principal investigator 1 Amgen Inc. $17,782.90 06/08/2025 Non-covered Recipient Entity
ACCELLACARE OF RALEIGH
A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Impact of Maridebart Cafraglutide on Cardiovascular Outcomes in Participants With Atherosclerotic Cardiovascular Disease and Overweight or Obesity No dispute reported 06/30/2026 1246638704
Principal investigator 1 ABBVIE INC. $133.65 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490383
Principal investigator 1 ABBVIE INC. $1,500.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202490385
Principal investigator 1 H. Lundbeck A S $350.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770805
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,510.95 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184204261
Principal investigator 1 TOLMAR, INC. $1,580.00 06/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323226
Principal investigator 1 ModernaTX, Inc. $330.00 06/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991882
Principal investigator 1 ModernaTX, Inc. $3,321.28 06/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991996
Principal investigator 1 ABBVIE INC. $7,762.50 06/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202487979
Principal investigator 1 ModernaTX, Inc. $9,501.15 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991904
Principal investigator 1 ModernaTX, Inc. $39,199.65 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991916
Principal investigator 1 ModernaTX, Inc. $832.02 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991920
Principal investigator 1 ModernaTX, Inc. $6,509.82 05/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991994
Principal investigator 1 TOLMAR, INC. $11,381.85 05/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323216
Principal investigator 1 TOLMAR, INC. $3,075.30 05/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323219
Principal investigator 1 TOLMAR, INC. $81.00 05/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
TOL-CLAR-20024 No dispute reported 06/30/2026 1237323223
Principal investigator 1 BioNTech SE $693.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021819
Principal investigator 1 BioNTech SE $234.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021865
Principal investigator 1 BioNTech SE $300.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021874
Principal investigator 1 BioNTech SE $144.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022001
Principal investigator 1 BioNTech SE $47.95 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022005
Principal investigator 1 BioNTech SE $693.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022087
Principal investigator 1 H. Lundbeck A S $350.00 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251770281
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,457.81 05/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184194937
Principal investigator 1 PFIZER INC. $75.00 05/08/2025 Non-covered Recipient Entity
Accellacare Us Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228833417
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,641.19 05/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184193805
Principal investigator 1 ABBVIE INC. $7,524.56 05/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202483685
Principal investigator 1 ModernaTX, Inc. $830.32 05/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991928
Principal investigator 1 ABBVIE INC. $44.55 05/06/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202482019
Principal investigator 1 BioNTech SE $8,523.18 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021815
Principal investigator 1 ModernaTX, Inc. $1,664.04 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991902
Principal investigator 1 ModernaTX, Inc. $8,600.01 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991912
Principal investigator 1 ModernaTX, Inc. $1,070.82 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991918
Principal investigator 1 ModernaTX, Inc. $44,496.90 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991982
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $17,949.61 04/28/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184190781
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,427.46 04/23/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184189087
Principal investigator 1 BioNTech SE $600.00 04/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021853
Principal investigator 1 BioNTech SE $302.77 04/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021857
Principal investigator 1 BioNTech SE $600.00 04/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022093
Principal investigator 1 BioNTech SE $600.00 04/22/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249022098
Principal investigator 1 ModernaTX, Inc. $13,285.12 04/16/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991956
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,213.73 04/15/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184183428
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $4,427.46 04/08/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184182084
Principal investigator 1 ABBVIE INC. $18,522.00 04/03/2025 Non-covered Recipient Entity
ACCELLACARE US INC
Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202470728
Principal investigator 1 H. Lundbeck A S $2,032.77 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769175
Principal investigator 1 H. Lundbeck A S $350.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251769212
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,051.30 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180848
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180868
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $230.85 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180910
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $68.31 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180912
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,080.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180914
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $283.50 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180936
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $570.00 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180938
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,362.50 04/01/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184180940
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 03/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184178892
Principal investigator 1 ModernaTX, Inc. $7,659.69 03/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991908
Principal investigator 1 ModernaTX, Inc. $24,628.86 03/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991930
Principal investigator 1 ModernaTX, Inc. $37,787.05 03/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991980
Principal investigator 1 BioNTech SE $693.00 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021785
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,695.38 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174620
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $500.00 03/19/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184174626
Principal investigator 1 ABBVIE INC. $267.30 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202462418
Principal investigator 1 ABBVIE INC. $534.60 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
M23-714 - Study of Oral Ubrogepant to Assess Adverse Events and Change in Disease Activity in Adult Participants With Menstrual Migraine No dispute reported 06/30/2026 1202462423
Principal investigator 1 BioNTech SE $3,465.00 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021783
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $8,921.08 03/11/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184170922
Principal investigator 1 Eli Lilly and Company $21.78 03/06/2025 Non-covered Recipient Entity
TRIANGLE MEDICAL RESEARCH ASSOCIATES LLC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187893768
Principal investigator 1 BioNTech SE $90.42 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021803
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $6,130.22 03/04/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184156780
Principal investigator 1 ModernaTX, Inc. $8,541.24 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991890
Principal investigator 1 ModernaTX, Inc. $27,841.32 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991892
Principal investigator 1 ModernaTX, Inc. $832.02 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991924
Principal investigator 1 ModernaTX, Inc. $5,718.82 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991932
Principal investigator 1 ModernaTX, Inc. $24,367.35 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991952
Principal investigator 1 ModernaTX, Inc. $1,577.61 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991962
Principal investigator 1 ModernaTX, Inc. $71,766.20 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991976
Principal investigator 1 ModernaTX, Inc. $2,521.57 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991978
Principal investigator 1 ModernaTX, Inc. $74.61 02/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252992004
Principal investigator 1 H. Lundbeck A S $100.00 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767728
Principal investigator 1 H. Lundbeck A S $53.00 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767739
Principal investigator 1 H. Lundbeck A S $700.00 02/25/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767758
Principal investigator 1 ModernaTX, Inc. $1,342.98 02/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991942
Principal investigator 1 ModernaTX, Inc. $149.22 02/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991922
Principal investigator 1 H. Lundbeck A S $6,621.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251767429
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,774.25 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154152
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,506.60 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154154
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $189.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154156
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $456.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154158
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $25,254.32 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154472
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $342.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154560
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $1,290.60 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154570
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $189.00 02/18/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184154574
Principal investigator 1 PFIZER INC. $36,574.78 02/06/2025 Non-covered Recipient Entity
Accellacare Us Inc
A PHASE 23 RANDOMIZED DOUBLEBLIND PLACEBO CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ORAL ZAVEGEPANT IN MIGRAINE PREVENTION No dispute reported 06/30/2026 1228831888
Principal investigator 1 H. Lundbeck A S $18,255.00 02/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766995
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $3,083.94 02/05/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184152492
Principal investigator 1 Eli Lilly and Company $430.00 01/31/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187887696
Principal investigator 1 ModernaTX, Inc. $43.89 01/30/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991926
Principal investigator 1 H. Lundbeck A S $20,440.00 01/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766789
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,847.69 01/29/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149842
Principal investigator 1 Eli Lilly and Company $8,753.80 01/27/2025 Non-covered Recipient Entity
RHEUMATOLOGY CENTER OF HOUSTON
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187889538
Principal investigator 1 ModernaTX, Inc. $12,360.25 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991900
Principal investigator 1 ModernaTX, Inc. $39,620.34 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991936
Principal investigator 1 ModernaTX, Inc. $4,426.21 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991940
Principal investigator 1 ModernaTX, Inc. $3,800.46 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991944
Principal investigator 1 ModernaTX, Inc. $61,979.90 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991984
Principal investigator 1 ModernaTX, Inc. $5,043.14 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991998
Principal investigator 1 ModernaTX, Inc. $3,155.22 01/27/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252992000
Principal investigator 1 GlaxoSmithKline, LLC. $11,815.15 01/24/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A PHASE 3, 52-WEEK, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARA No dispute reported 06/30/2026 1192165103
Principal investigator 1 Eli Lilly and Company $139,407.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3 RANDOMIZED DOUBLE BLIND STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF ONCE DAILY ORAL LY3502970 COMPARED WITH PLACEBO IN ADULT PARTICIPANTS WITH OBESITY OR OVERWEIGHT AND TYPE 2 DIABETES (ATTAIN-2) No dispute reported 06/30/2026 1187888952
Principal investigator 1 Eli Lilly and Company $95,887.00 01/21/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, EVENT-DRIVEN STUDY TO INVESTIGATE THE EFFECT OF RETATRUTIDE ON THE INCIDENCE OF MAJOR ADVERSE CARDIOVASCULAR EVENTS AND THE DECLINE IN KIDNEY FUNCTION IN PARTICIPANTS WITH BODY MASS INDEX GREATER THAN 27 KG M2 AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE AND OR CHRONIC KIDNEY DISEASE No dispute reported 06/30/2026 1187889102
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $15,155.91 01/21/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184149038
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $5,918.94 01/17/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184148069
Principal investigator 1 Novartis Pharmaceuticals Corporation $1,500.20 01/15/2025 Non-covered Recipient Entity
PMG RESEARCH OF RALEIGH
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190308048
Principal investigator 1 BioNTech SE $4,706.16 01/14/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021777
Principal investigator 1 Novartis Pharmaceuticals Corporation $26,897.00 01/14/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH LLC PMG RESEARCH INC
A Randomized Double-blind, Placebo-controlled, Multicenter Trial Assessing the Impact of Lipoprotein (a) Lowering With TQJ230 on Major Cardiovascular Events in Patients With Established Cardiovascular Disease No dispute reported 06/30/2026 1190298515
Principal investigator 1 BioNTech SE $1,181.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021773
Principal investigator 1 BioNTech SE $153.44 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021787
Principal investigator 1 BioNTech SE $912.42 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021789
Principal investigator 1 BioNTech SE $110.97 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021791
Principal investigator 1 BioNTech SE $150.70 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021793
Principal investigator 1 BioNTech SE $271.26 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021795
Principal investigator 1 BioNTech SE $576.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021797
Principal investigator 1 BioNTech SE $396.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021799
Principal investigator 1 BioNTech SE $192.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
BNT163-01 No dispute reported 06/30/2026 1249021801
Principal investigator 1 Eli Lilly and Company $430,549.00 01/07/2025 Non-covered Recipient Entity
PIEDMONT MEDICAL RESEARCH ASSOCIATES INC
A PHASE 3, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO INVESTIGATE THE EFFECT OF LEPODISIRAN ON THE REDUCTION OF MAJOR ADVERSE CARDIOVASCULAR EVENTS IN ADULTS WITH ELEVATED LIPOPROTEIN(A) WHO HAVE ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR ARE AT RISK FOR A FIRST CARDIOVASCULAR EVENT - ACCLAIM-LP(A) No dispute reported 06/30/2026 1187888956
Principal investigator 1 H. Lundbeck A S $682.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766302
Principal investigator 1 H. Lundbeck A S $115.00 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
INTERVENTIONAL, RANDOMIZED, DOUBLE-BLIND, PARALLEL-GROUP, PLACEBO-CONTROLLED, DOSE-FINDING TRIAL OF LU AG09222 FOR THE PREVENTION OF MIGRAINE IN PARTICIPANTS WITH UNSUCCESSFUL PRIOR PREVENTIVE TREATMENTS No dispute reported 06/30/2026 1251766323
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $23,742.45 01/07/2025 Non-covered Recipient Entity
ACCELLACARE US INC
A RANDOMIZED, DOUBLE-BLIND STUDY OF THE EFFICACY AND SAFETY OF TREVOGRUMAB, WITH OR WITHOUT GARETOSMAB, IN ADDITION TO SEMAGLUTIDE IN PATIENTS WITH OBESITY No dispute reported 06/30/2026 1184146192
Principal investigator 1 ModernaTX, Inc. $81.96 01/06/2025 Non-covered Recipient Entity
ACCELLACARE-RALEIGH
A Study to Investigate the Safety and Efficacy of mRNA-1403 in Participants ?18 Years of Age for the Prevention of Acute Gastroenteritis No dispute reported 06/30/2026 1252991992